This project is funded by:
Senescence is a process where cells cease dividing and undergo distinctive phenotypic changes. Senescence has a key role in the aging process and has also been implicated as a major cause of age-related disease through the accumulation of senescence cells which leads to age-related physiological decline. One such ageing disease is AF. When a patient is diagnosed with heart arrythmia, it not known whether he or she can develop more severe form and or permanent AF. In this project, we aim to identify candidate biomarkers that could predict trajectory of AF. We propose to deploy an integrative multi-omics approach to utilising cellular senescence biomarkers as early predictors of heart function maintenenece or decline. Existing datasets include proteomics, trancriptomics and metagenomics of several chronic diseases including AF. The candidate will tease out heart specific senescence signatures using all these datasets.
In this project, the researcher will:
1) Analyse multiple omic datasets of AF and compare to other chronic ageing disease datasets available at the Personalised Medicine Centre to identify heart specific senescence biomarkers
2) Perform proteomic studies on plasma samples from AF patients to identify senescence markers
3) Undertake machine learning/AI studies to determine and independently validate biomarkers for progression to permanent AF
4) Publish research and review articles in top tier journals
The proposed project will be based at the Personalised Medicine Centre within the School of Medicine at Ulster University. It will combine laboratory sciences and data analytics. The ideal candidate will have B.Sc/M.SC in Biological/Computational Sciences. Experience in handling/analysing large omic datasets is desired but not essential. The project will provide the student with training in a wide range of highly transferable skills such as bioinformatics (machine learning and AI) and laboratory techniques (molecular biology, trancriptomics and proteomics).
Important Information: Applications for more than one PhD studentship are welcome, however if you apply for more than one PhD project within Medicine, your first application on the system will be deemed your first-choice preference and further applications will be ordered based on the sequential time of submission. If you are successfully shortlisted, you will be interviewed only on your first-choice application and ranked accordingly. Those ranked highest will be offered a PhD studentship. In the situation where you are ranked highly and your first-choice project is already allocated to someone who was ranked higher than you, you may be offered your 2nd or 3rd choice project depending on the availability of this project.
Applicants should hold, or expect to obtain, a First or Upper Second Class Honours Degree in a subject relevant to the proposed area of study.
We may also consider applications from those who hold equivalent qualifications, for example, a Lower Second Class Honours Degree plus a Master’s Degree with Distinction.
In exceptional circumstances, the University may consider a portfolio of evidence from applicants who have appropriate professional experience which is equivalent to the learning outcomes of an Honours degree in lieu of academic qualifications.
If the University receives a large number of applicants for the project, the following desirable criteria may be applied to shortlist applicants for interview.
The University is an equal opportunities employer and welcomes applicants from all sections of the community, particularly from those with disabilities.
Appointment will be made on merit.
This project is funded by:
Our fully funded PhD scholarships will cover tuition fees and provide a maintenance allowance of £19,237 (tbc) per annum for three years (subject to satisfactory academic performance). A Research Training Support Grant (RTSG) of £900 per annum is also available.
These scholarships, funded via the Department for the Economy (DfE) and the Vice Chancellor’s Research Scholarships (VCRS), are open to applicants worldwide, regardless of residency or domicile.
Applicants who already hold a doctoral degree or who have been registered on a programme of research leading to the award of a doctoral degree on a full-time basis for more than one year (or part-time equivalent) are NOT eligible to apply for an award.
Due consideration should be given to financing your studies.
The role of senescence in the pathogenesis of atrial fibrillation: a target process for health improvement and drug development: Guo, G., Watterson, S., Zhang, S-D., Bjourson, A., McGilligan, V., Peace, A. & Rai, T. S. Ageing research reviews. 2021
Senescence Biomarkers CKAP4 and PTX3 Stratify Severe Kidney Disease Patients. McCallion, S., McLarnon, T., Cooper, E., English, A. R., Watterson, S., Chemaly, M. E., McGeough, C., Eakin, A., Ahmed, T., Gardiner, P., Pendleton, A., Wright, G., McGuigan, D., O’Kane, M., Peace, A., Kuan, Y., Gibson, D. S., McClean, P. L., Kelly, C. & McGilligan, V. Rai TS et al, , 26 Sept 2024, (Published online) In: Cells. 13, 19, p. 1-18 18 p., 1613.
Senescence Signatures Predict Hospitalization Risk and Severity in COVID-19 Patients Lynch, S. M., McLarnon, T., Cooper, E., McDaid, D., Guo, G., McLaughlin, J., McGilligan, V. E., Watterson, S., Shukla, P., Zhang, S.-D., Bucholc, M., English, A., Freeman, L., Irwin, R. E., Peace, A., O’Kane, M., Kelly, M., Bhavsar, M., Murray, E. K. & Gibson, D. S. & Rai TS 23 Sept 2024, (Published online) In: Aging Biology. 2, 1, p. 1-14 14 p., 20240035.
Potential Plasma Proteins (LGALS9, LAMP3, PRSS8 and AGRN) as Predictors of Hospitalisation Risk in COVID-19 Patients
McLarnon, T., McDaid, D., Lynch, S. M., Cooper, E., McLaughlin, J., McGilligan, V. E., Watterson, S., Shukla, P., Zhang, S.-D., Bucholc, M., English, A., Peace, A., O’Kane, M., Kelly, M., Bhavsar, M., Murray, E. K., Gibson, D. S., Walsh, C. P., Bjourson, A. J. & Rai, T. S., 17 Sept 2024, (Published online) In: Biomolecules. 14, 9, p. 1-17 17 p., 1163.
Role of Senescence and Aging in SARS-CoV-2 Infection and COVID-19 Disease. Lynch, S.M.; Guo, G.; Gibson, D.S.; Bjourson, A.J.; Rai, T.S. Cells 2021, 10, 3367. https://doi.org/10.3390/cells10123367
Deep learning in systems medicine. Wang H, Guillot EP, Comte B, de Miranda JL, Spiwok V, Chorbev I, Castiglione F, Tieri P, Watterson S, McAllister R, Malaquias TM, Rai TS, Zheng H. Briefings in Bioinformatics 2020.
The histone chaperone HIRA promotes the induction of host innate immune defences in response to HSV-1 infection. McFarlane S, Orr A, Roberts APE, Conn KL, Iliev V, Loney C, da Silva Filipe A, Smollett K, Gu Q, Robertson N, Adams PD, Rai TS, Boutell C. PLoS Pathogens 2019.
Histone chaperone HIRA deposits histone H3.3 onto foreign viral DNA and contributes to anti-viral intrinsic immunity. Rai TS*, Glass M, Cole JJ, Rather MI, Marsden M, Neilson M, Humphreys I, Everett R, Adams PD*, Nucleic Acids Research 2017
Ubinuclein-1 confers histone H3.3-specific-binding by the HIRA histone chaperone complex. Ricketts DM, Frederick B, Hoff H, Tang Y, Schultz DC, Rai TS, Grazia Vizioli M, Adams PD, Marmorstein R. Nature Communications. 2015 Jul 10;6:7711.
HIRA orchestrates non-canonical dynamic chromatin in senescence and is required for suppression of neoplasia. Rai TS, Cole JC, Nelson DM, Dikovskaya D, McBryan T, Faller W, Tuyn Jv, Morrice N, Hewitt RN, Manoharan I, Pchelintsev NA, Ivanov A, Brock C, Drotar ME, Nixon C, Clark W, Sansom OJ, King A, Blyth K, Adams PD. Genes and Development 2014 Dec 15; 28(24): 2712-25.
p53 status determines the role of autophagy in pancreatic tumour development. Rosenfeldt MT, O'Prey J, Morton JP, Nixon C, MacKay G, Mrowinska A, Au A, Rai TS, Zheng L, Ridgway R, Adams PD, Anderson KI, Gottlieb E, Sansom OJ, Ryan KM. Nature. 2013 Dec 12; 504(7479):296-300.
Senescent cells harbour features of the cancer epigenome. Cruickshanks HA, McBryan T, Nelson DM, Vanderkraats ND, Shah PP, van Tuyn J, Rai TS, Brock C, Donahue G, Dunican DS, Drotar ME, Meehan RR, Edwards JR, Berger SL, Adams PD. Nature Cell Biology 2013 Dec; 15(12):1495-506
Sprouty2, PTEN, and PP2A interact to regulate prostate cancer progression. Patel R, Gao M, Ahmad I, Fleming J, Singh LB, Rai TS, McKie AB, Seywright M, Barnetson RJ, Edwards J, Sansom OJ, Leung HY. J Clin Invest. 2013 Mar 1;123(3):1157-75.
Submission deadline
Monday 3 February 2025
04:00PM
Interview Date
W/C 10 March 2025
Preferred student start date
15 September 2025
Telephone
Contact by phone
Email
Contact by email